Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus.

Next Previous
Trial Profile

An 8-Week Randomized, Double-Blind, Parallel-Group, Multi-Center, Active-Controlled Dose Escalation Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ (300/25 mg) Compared to Amlodipine (10 mg) in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aliskiren/hydrochlorothiazide (Primary) ; Amlodipine
  • Indications Essential hypertension; Hypertension
  • Focus Biomarker; Therapeutic Use
  • Acronyms ASTRIDE
  • Sponsors Novartis

Most Recent Events

  • 01 Dec 2011 Results published in the Journal of Clinical Hypertension (Greenwich).
  • 24 Sep 2010 Results presented at the 46th Annual Meeting of the European Association for the Study of Diabetes.
  • 01 May 2010 Primary endpoint 'Systolic-blood-pressure' has been met according to the results published at the 25th Annual Scientific Meeting of the American Society of Hypertension.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top